Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV ...

Morgan Stanley is a buy on weakness with strong dividend growth and projected revenue growth in Q4 2024 and early 2025. Click for our MS earnings preview.

A good investment trust can act as a solid anchor for a Stocks and Shares ISA, helping investors maintain steady long-term ...

JP Morgan analyst Kian Abouhossein maintained a Neutral rating and boosted the price target from $100 to $104 on Dec. 6, 2024 ...

Morgan Stanley expects improving freight conditions and upcoming emissions regulations to boost global truck manufacturers in 2025, with Daimler (OTC:MBGAF) Truck Holding AG (F:DTGGe) and Volvo ...

Wall Street’s largest investment banks are looking to award traders and dealmakers with their largest bonus increases since the pandemic, with ...

Morgan Stanley Investment Management (MSIM) announced today that the 1GT private climate equity strategy (1GT) participated in a ?115 million fundraise for XOCEAN (company), a leading provider of ...

Global equity issuance rose 20% last year, but stock market launches have so far lagged that increase, remaining far below ...

Andrew Forrest has taken a ‘bring it on’ stance in response to ExxonMobil’s defamation lawsuit, which it has filed against ...

Morgan Stanley upgraded Vir Biotechnology (NASDAQ:VIR) to Overweight from Equal Weight on Thursday after the cancer drug ...

Morgan Stanley (NYSE: MS) is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 42 ...

Wall Street's biggest banks are set to reward their traders and dealmakers with their biggest bonus increase since the ...